Simplex Trading’s Repare Therapeutics RPTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-18,300
| Closed | -$47.6K | – | 9998 |
|
|
2025
Q4 | $47.6K | Buy |
+18,300
| New | +$36.8K | ﹤0.01% | 5700 |
|
|
2024
Q3 | – | Sell |
-3,900
| Closed | -$12K | – | 9420 |
|
|
2024
Q2 | $12K | Buy |
3,900
+100
| +3% | +$357 | ﹤0.01% | 7320 |
|
|
2024
Q1 | $17K | Buy |
3,800
+1,200
| +46% | +$7.69K | ﹤0.01% | 7233 |
|
|
2023
Q4 | $18K | Buy |
+2,600
| New | +$14.5K | ﹤0.01% | 7016 |
|
|
2023
Q3 | – | Sell |
-9,200
| Closed | -$97K | – | 9655 |
|
|
2023
Q2 | $97K | Buy |
9,200
+5,200
| +130% | +$53.6K | ﹤0.01% | 5125 |
|
|
2023
Q1 | $39K | Buy |
+4,000
| New | +$45.9K | ﹤0.01% | 6210 |
|
|
2022
Q4 | – | Sell |
-300
| Closed | -$3K | – | 10233 |
|
|
2022
Q3 | $3K | Buy |
+300
| New | +$3.86K | ﹤0.01% | 9148 |
|
|
2022
Q2 | – | Sell |
-100
| Closed | -$1K | – | 10918 |
|
|
2022
Q1 | $1K | Sell |
100
-200
| -67% | -$2.97K | ﹤0.01% | 10136 |
|
|
2021
Q4 | $6K | Buy |
+300
| New | +$7.07K | ﹤0.01% | 9431 |
|
Simplex Trading's RPTX Position: Q3 2025 in Review
Simplex Trading sold out of Repare Therapeutics (RPTX) in Q3 2025, closing a stake of 8,093 shares — an estimated $13K sold.
Simplex Trading first reported a position in RPTX in Q4 2021 and held it in 15 quarters. The position peaked at $233K in Q3 2023. 45 funds tracked by Wall St. Rank hold RPTX as of Q3 2025.
- Simplex Trading reported no remaining Repare Therapeutics position as of Q3 2025 after selling out during the quarter.
- Simplex Trading sold 8,093 Repare Therapeutics shares in Q3 2025, an estimated $13K.
- Simplex Trading first reported a position in Repare Therapeutics in Q4 2021 and held it in 15 quarters.
- Simplex Trading's Repare Therapeutics position peaked at $233K in Q3 2023.
- 45 funds tracked by Wall St. Rank held Repare Therapeutics as of Q3 2025.
Based on Simplex Trading's 13F filing for Q3 2025, filed 12 Nov 2025.